enGene Therapeutics Inc. (ENGN)
↓ Download CSVKey ratios (FY2025)
-69.9%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Income | -$123.17M | -$62.30M | -$26.06M | -$19.43M | — |
| Net Income | -$117.30M | -$55.14M | -$99.92M | -$24.46M | — |
| EPS (Diluted) | $2.29 | $1.46 | $151.22 | $44.30 | — |
| Total Assets | $221.47M | $311.17M | $86.96M | $23.91M | — |
| Total Liabilities | $53.76M | $38.56M | $14.47M | $47.41M | — |
| Shareholders' Equity | $167.71M | $272.61M | $72.49M | -$76.61M | -$53.44M |
| Cash & Equivalents | $50.15M | $173.00M | $81.52M | $20.43M | — |
| Operating Cash Flow | -$99.24M | -$48.28M | -$24.74M | -$17.59M | — |
| Capital Expenditures | $1.49M | $925.0K | $318.0K | $153.0K | — |
| Shares Outstanding | 52.02M | 50.98M | 23.20M | 665.8K | — |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | — | — |